Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a landmark study that may herald a quicker, more tailored treatment for the millions of people around the world living with tuberculosis (TB), UK researchers have shown how our understanding of TB’s genetic code is now so detailed that we can now predict which commonly used anti-TB drugs are best for treating a patient’s infection and which are not.

This study, led by the international CRyPTIC consortium based at the University of Oxford and facilitated by the United Kingdom government’s 100,000 Genomes Project in partnership with Public Health England, is by far the largest of its kind, covering over 10,000 TB genomes from 16 equal partner countries around the globe.

Find out more (NIHR BRC website)

Similar stories

Oxford expands the Cartography collaboration with Janssen

The University of Oxford announced today that it has expanded a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation

Multiplex Serology: the first step towards looking at 20 infectious agents in half a million people

Certain infectious agents are recognised causes of cancer and other chronic diseases. To understand the pathological mechanisms underlying such relationships, we designed a Multiplex Serology platform to measure quantitative antibody responses against 45 antigens from 20 infectious agents.

Outbreak: fighting coronavirus

In a new Oxford Science Blog, Charvy Narain (Communications & Public Engagement Manager, Radcliffe Department of Medicine) talks to some of the Oxford University researchers coming together to fight the novel Coronavirus outbreak.

Researchers find new cells that repair tissue

Researchers from Nuffield Department of Medicine have discovered that a newly discovered group of cells can help repair tissues in the body.

Rapidly spreading multidrug-resistant parasites render frontline malaria drug ineffective in southeast Asia

A rapidly evolving multi-drug resistant lineage of P. falciparum malaria parasites continues to spread in South East Asia, leading to alarmingly high treatment failure rates in Cambodia, Thailand and Vietnam for DHA-piperaquine, one of the world’s most important anti-malaria drugs.

New study shows faster way to cure vivax malaria

A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated and just as effective as the current standard 14 day regimen, according to a study published this week in The Lancet. These findings have important implications for the treatment and elimination of vivax malaria in the Asia Pacific.